Anti-Human TCR Vα24-Jα18 (iNKT cell)- Purified in vivo PLATINUM™ Functional Grade

Anti-Human TCR Vα24-Jα18 (iNKT cell)- Purified in vivo PLATINUM™ Functional Grade

Product No.: T1705

[product_table name="All Top" skus="T705"]

- -
- -
Clone
6B11
Target
TCR Vα24-Jα18
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
TCR Vα24-Jα18, TCR Vα24-JαQ, invariant NKT cell, iNKT
Isotype
Mouse IgG1 κ
Applications
CyTOF®
,
FC
,
in vivo

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Recommended Dilution Buffer
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<0.5 EU/mg as determined by the LAL method
Purity
≥98% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Working Concentration
0.5 mg/ml
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this TCR Vα24-Jα18 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
Additional Applications Reported In Literature ?
CyTOF®
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone 6B11 recognizes the invariant CDR3 region of the human Vα24-Jα18 TCR.
Background
TCR Vα24-Jα18 antibody, 6B11, recognizes the CDR3 region of the V alpha 24 and J alpha 18 TCR alpha locus (Vα24-Jα18). The Vα24-Jα18 semi-invariant TCR is expressed on a highly conserved T cell subset, named invariant natural killer T (iNKT cells), which also express NK cell-associated molecules. The Vα24-Jα18 TCR recognizes lipid antigens, such as α-galactosylceramide (α-GalCer), presented by the MHC class I-like molecule CD1d1. Following activation, iNKT cells rapidly proliferate and produce large amounts of IL-4, IFNγ, and cytolytic mediators2,3. iNKT cells have both inflammatory and immunoregulatory functions and are implicated in anti-tumor immunity, protection against infections, suppression of autoimmunity, and the development of inflammatory diseases4.
Antigen Distribution
The Vα24-Jα18 TCR is expressed on iNKT cells.
Ligand/Receptor
Glycolipid loaded CD1d
NCBI Gene Bank ID
Research Area
Immunology

References & Citations

1. Van Kaer L., et al. (2004) Nat Rev Immunol. 4(3):231-7
2. Teyton L., et al. (2006) Annu Rev Immunol. 25:297–336
3. Kronenberg M. (2004) Annu Rev Immunol. 23:877–900
4. Van Kaer L & Wu L. (2018) Front Immunol. 9:519
CyTOF®
Flow Cytometry
in vivo Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.